USE OF LORAZEPAM FOR PEDIATRIC STATUS EPILEPTICUS (COHORT 2)

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中出现。列出的机构是中心的机构，不一定是研究者的机构。这项多中心研究的目的是研究劳拉西泮治疗儿童癫痫持续状态的药代动力学。该研究有两个队列。第 1 组适用于在主动癫痫发作时可以入组/给药的患者，第 2 组适用于将选择性入组/给药的患者。第 2 组的排除标准已更改为排除患者，如果他们患有不明原因的肾脏或肝脏疾病，其程度大于正常限度的两倍或患者基线值的两倍。样本量从60名患者调整为100名患者，研究期限延长至2006年5月1日。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the multi-center study is to look at the pharmacokinetics of lorazepam for the treatment of pediatric status epileticus. The study has two cohorts. Cohort 1 is for patients that can be enrolled/dosed while actively seizing and cohort 2 is for patients that will be electively enrolled/dosed. The exclusion criterion for cohort 2 has been changed to excluded patients if they have unexplained renal or hepatic disease greater than twice the limit than normal or 2-fold increase of the patients baseline value. The sample size has been adjusted from 60 to 100 patients and the study has been extended until May 1, 2006.